--- title: Reduce Recruitment Risk in Pharma Through Representation | Acclinate description: "Representation can make or break your clinical trial. Learn how to reduce recruitment risk in pharma: Build trust from the start with Acclinate." image: https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Reduce-Recruitment-Risk-in-Pharma-Through-Representation.jpg --- [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate-logo.png?width=2000&height=497&name=Acclinate-logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [eDICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [Contract Research Organizations](https://www.acclinate.com/solutions/for-cros) - [Partners](https://www.acclinate.com/solutions/community-partners) - Company - [About Us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [News](https://news.acclinate.com) - Resources - [Resource Library](https://www.acclinate.com/resources) - [Blog](https://blog.acclinate.com) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [Glossary](https://www.acclinate.com/glossary) - [FAQ](https://www.acclinate.com/faq) - [Talk to Our Team](https://info.acclinate.com/get-in-touch) [![Talk to Our Team](https://no-cache.hubspot.com/cta/default/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302.png)](https://cta-redirect.hubspot.com/cta/redirect/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302) [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate_Logo.png?width=500&height=149&name=Acclinate_Logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [**NOWINCLUDED**Acclinate’s B2C community platform ](https://www.acclinate.com/products/nowincluded-the-community) - [**e-DICT**Acclinate’s patented AI-powered technology ](https://www.acclinate.com/products/e-dict) - Solutions - [**Pharmaceutical Companies**Community-driven recruitment and real-world insights to support diverse, compliant clinical trials. ](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [**Contract Research Organization (CRO)**Scalable patient engagement and recruitment solutions that reduce risk and improve enrollment timelines. ](https://www.acclinate.com/solutions/for-cros) - [**Partners**Trusted partnerships that connect research opportunities with the communities they aim to serve. ](https://www.acclinate.com/solutions/community-partners) - Company - [**About us**We help clinical research teams reach diverse communities, build trust, and improve trial participation. ](https://www.acclinate.com/about) - [**Careers**Join a mission-driven team advancing inclusive clinical research and community-powered health innovation. ](https://www.acclinate.com/careers) - Resources - [**Resources Hub** ](https://www.acclinate.com/resources) - [**Glossary** ](https://www.acclinate.com/glossary) - [**Press Kit** ](https://www.acclinate.com/press-kit) - [**Events** ](https://www.acclinate.com/events) - [**Blog** ](https://blog.acclinate.com/) - [**News** ](https://news.acclinate.com/) - [![](https://cdn.prod.website-files.com/695fbca039298e2117988a78/69e7b588548c7ad7bd8ab0bc_9dd915489696393dc63d7785ee2e52c7_Question%20mark%20image.png) **FAQs** ](https://www.acclinate.com/faq) - [ Contact Us ](https://www.acclinate.com/contact-us) Stay up to date Get news directly in your inbox Topic All - [Affective Trust ](https://blog.acclinate.com/tag/affective-trust) - [Announcement ](https://blog.acclinate.com/tag/announcement) - [Clinical Research Software ](https://blog.acclinate.com/tag/clinical-research-software) - [Clinical Trial Recruitment Strategies ](https://blog.acclinate.com/tag/clinical-trial-recruitment-strategies) - [Community ](https://blog.acclinate.com/tag/community) - [Diversity in Clinical Trials ](https://blog.acclinate.com/tag/diversity-in-clinical-trials) - [e-DICT™ ](https://blog.acclinate.com/tag/e-dict) - [FDA Diversity Plan ](https://blog.acclinate.com/tag/fda-diversity-plan) - [FDA Guidance: Diversity in Clinical Trials ](https://blog.acclinate.com/tag/fda-guidance-diversity-in-clinical-trials) - [Health Equity ](https://blog.acclinate.com/tag/health-equity) - [Partnerships ](https://blog.acclinate.com/tag/partnerships) - [Representation in Healthcare ](https://blog.acclinate.com/tag/representation-in-healthcare) [Clinical Trial Recruitment Strategies](https://blog.acclinate.com/topic/clinical-trial-recruitment-strategies) # Reduce Recruitment Risk in Pharma Through Representation Representation can make or break your clinical trial. Learn how to reduce recruitment risk in pharma: Build trust from the start with Acclinate. ![Reduce Recruitment Risk in Pharma Through Representation](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Reduce-Recruitment-Risk-in-Pharma-Through-Representation.jpg) Clinical Trial Diversity: What Does It Really Mean? Clinical trials are critical for evaluating the safety and effectiveness of medical devices and pharmaceutical products. The results of trials guide t... Read More ![ Acclinate](https://blog.acclinate.com/hubfs/69b96486c4b036c19f462c19_acclinate-logo.png) [Acclinate](https://blog.acclinate.com/author/acclinate) Acclinate turns trust and data into better representation. Share this Post: [**](https://www.facebook.com/sharer/sharer.php?u=https://blog.acclinate.com/reduce-recruitment-risk-in-pharma-through-representation) [**](https://twitter.com/home?status=https://blog.acclinate.com/reduce-recruitment-risk-in-pharma-through-representation) [** ](https://www.linkedin.com/shareArticle?mini=true&url=https://blog.acclinate.com/reduce-recruitment-risk-in-pharma-through-representation&title=Reduce%20Recruitment%20Risk%20in%20Pharma%20Through%20Representation%20|%20Acclinate) Stay up to date Get news directly in your inbox **Key Takeaways and Learnings**  - Underrepresentation slows recruitment, increases dropout risk, and weakens data reliability. - Proactive inclusion strategies can mitigate trial delays through community-rooted trust. - Acclinate helps reduce recruitment risk in pharma by building affective trust and fostering sustained, community-rooted engagement. - Want a deeper dive into this strategy? Download The Ultimate Guide to Advancing Health Equity in Clinical Trials.   Clinical trial delays cost time, money, and, most importantly, patient access to potentially life-changing therapies. But they’re not inevitable: Many delays arise because sponsors, CROs, and recruiters overlook underrepresented communities—particularly communities of color.  When these groups aren’t *genuinely* engaged early in the recruitment process, they’re less likely to participate. [And without representation, new therapies may be less effective](https://www.kff.org/racial-equity-and-health-policy/issue-brief/racial-and-ethnic-disparities-in-access-to-medical-advancements-and-technologies/)—or less trusted—by the people who need them most. By integrating representation from day one, CROs and sponsors are [more likely to meet enrollment goals, retain participants, and collect real-world data that reflects the needs of all communities](https://blog.acclinate.com/on-budget-on-time-how-equity-can-improve-clinical-trial-roi).   Fully engaging communities of color in clinical research [helps ensure the therapies being tested are safe and effective](https://www.kff.org/racial-equity-and-health-policy/issue-brief/racial-and-ethnic-disparities-in-access-to-medical-advancements-and-technologies/) for everyone. This matters because race, ethnicity, and social determinants of health can influence how someone responds to a particular medication. Representation also builds credibility. [Black patients, for example, report greater trust in treatments](https://www.cancer.gov/news-events/cancer-currents-blog/2024/black-patients-beliefs-clinical-medical-research) when they see themselves represented in clinical research.   Acclinate helps sponsors and CROs reduce recruitment risk in pharma by centering inclusion from the very beginning. This approach provides access to valuable and largely overlooked communities, while helping [avoid unnecessary enrollment delays](https://ascopubs.org/doi/10.1200/JCO.22.00754).    [![Download Now – Before You Recruit: The Ultimate Guide to Advancing Health Equity in Clinical Trials](https://no-cache.hubspot.com/cta/default/19943632/interactive-188916301454.png) ](https://blog.acclinate.com/hs/cta/wi/redirect?encryptedPayload=AVxigLLsrhB1ZsGjwAJENouRGZ97aBGkNQYzmz6M8PtGDClEYi0bw4eASnFqPY%2FyQ9WcZk2F1gFknOHABrgEIeegP465LLVZdIxxU4YWw7OS0x1ENAMGmT8GvnvVpioz7%2FZq6Q2MrTTnpNFnJjDQkrb22r7Y6Wp3CTRB2toAPuBWcHSxhHLhV%2Fp7ZAjqhChzqWAIIF%2BWI8UtdoTlt96WlCxJpmNP4ndMeyQ3aKiR42SN2XecgXQ9rjDzVr9VNs7iPQsclw%3D%3D&webInteractiveContentId=188916301454&portalId=19943632) ## Why Representative Patient Enrollment Reduces Recruitment Risk A lack of representative recruitment strategies can derail clinical trials, leading to [missed enrollment targets, higher costs,](https://pmc.ncbi.nlm.nih.gov/articles/PMC11537200/) and weaker data. When research doesn’t authentically connect with communities of color, it risks slower recruitment, poorer retention, and the need for [costly post-marketing studies](https://www.appliedclinicaltrialsonline.com/view/the-impact-of-dei-ban-on-clinical-research-ecosystem) to fill evidence gaps.  Consider the following:  - [About 80% of US clinical trials miss enrollment deadlines](https://acrpnet.org/2024/04/12/barriers-to-clinical-trial-enrollment-focus-on-underrepresented-populations). - Up to [20% of clinical trials fail because of inadequate enrollment](https://www.cancernetwork.com/view/overcoming-obstacles-to-clinical-trial-recruitment-and-retention). - In a typical phase III clinical trial, [37% of research sites under-enroll.](https://link.springer.com/article/10.1007/s43441-023-00540-2) - Reports vary, but up [to 85% of clinical trials fail to recruit enough participants on time.](https://pmc.ncbi.nlm.nih.gov/articles/PMC10565197/#ref2) - [Drug launch delays cost an estimated $500,000 per day](https://pubmed.ncbi.nlm.nih.gov/38773058/), with some estimates as high as [$8 million per day](https://media.market.us/clinical-trials-statistics/).  When sponsors and CROs rely too heavily on familiar recruitment channels, they narrow their reach and increase the likelihood of expensive delays. In contrast, carefully targeted outreach efforts [bolster accessibility and engagement](https://pmc.ncbi.nlm.nih.gov/articles/PMC11963400/), which in turn [improve recruitment, representative patient enrollment, and retention](https://www.sciencedirect.com/science/article/pii/S245186542030017X), especially in communities of color.  Acclinate partners with sponsors and CROs to implement community-rooted, culturally informed strategies that improve enrollment for current trials and build the trust needed for long-term research involvement. ## **Mitigating Trial Delays Through Inclusion**  To reduce recruitment risk in pharma, inclusive practices must begin well before recruitment starts. Building representation early, through culturally relevant outreach, inclusive site selection, and trusted community partnerships, lays the foundation for faster study launches and stronger retention.  It's important to note that [health equity and ROI aren't mutually exclusive](https://blog.acclinate.com/on-budget-on-time-how-equity-can-improve-clinical-trial-roi). In fact, they're deeply connected. When research teams authentically engage underrepresented populations, they expand access and enrollment, improve participant trust and retention, and generate more reliable, review-ready data.   Traditional recruitment often fails because it lacks community insight. It’s not culturally relevant. It relies on cognitive trust, expecting facts and credentials to convince people to join a trial. But that approach may not work with communities of color and others who are justifiably skeptical about clinical research.   Acclinate focuses on *affective* trust, which prioritizes authentic, two-way communication as the foundation of equitable research engagement. Our [Affective Trust Framework ](https://www.youtube.com/watch?v=zYyqEZM9K7Y) takes a personal, culturally rooted, high-touch approach. Are you ready for truly representative patient enrollment? Download Acclinate’s [Mobilizing for Health Equity: 3 Steps to Engage Communities of Color](https://info.acclinate.com/3-steps-to-engage-communities-of-color).  ## **Acclinate’s Approach to Reduce Recruitment Risk in Pharma** With NOWINCLUDED and e-DICT™, Acclinate, sponsors and CROs can see community engagement as it unfolds. They get a real-time view of what’s working and what’s not. But these digital tools do more than collect data—they build relationships and translate community insight into action.   ### **Building Trust Through NOWINCLUDED**  [**NOWINCLUDED**, Acclinate’s digital engagement platform](https://nowincluded.com/), was built by and for communities of color. It fosters culturally relevant education, storytelling, and dialogue—connecting people around shared experiences and health journeys. Through discussions, surveys, and peer exchange, the platform surfaces the questions, barriers, and motivations that matter most to historically underrepresented communities. It also provides information on conditions and health resources while offering a space for meaningful connection. By supporting members as they take control of their medical journeys, it helps build affective, emotional, and communal trust.   ### **Predictive Precision With e-DICT™**  [e-DICT™ turns those NOWINCLUDED insights into strategy](https://www.acclinate.com/how-it-works). Sponsors and CROs can track community sentiment, engagement trends, and representation in real time. With predictive analytics and adaptive dashboards, researchers can see where momentum is building—or where trust is faltering. They can then adjust outreach strategies quickly and effectively.  Together, NOWINCLUDED and e-DICT™ create a powerful feedback loop: Insights from the community inform strategy, and strategy adapts in real time to deepen trust and drive participation. The impact is measurable—especially when applied in real-world trials.  ### **Success Story: Boosting Enrollment in Alzheimer’s Research**  Lightship partnered with Acclinate to increase representation in a [decentralized phase 3 Alzheimer’s trial](https://www.acclinate.com/alzheimers-disease-clinical-trial-case-study).   Black communities have long been underrepresented in neurology research, even though Alzheimer’s disease affects Black older adults at twice the rate of their white counterparts. Yet [only 1% to 3% of Black Americans are included in Alzheimer’s clinical drug research.](https://healthjournalism.org/blog/2024/08/researchers-aim-to-rectify-underrepresentation-of-black-women-in-alzheimers-studies/)  Using our NOWINCLUDED platform and culturally tailored education strategies, we helped increase the number of pre-screened participants by 3.8x in just four months. Of the 164 individuals Lightship pre-screened, 157 identified as Black or African American. Acclinate’s outreach identified 86 individuals who were eligible for screening.   When people feel seen, informed, and respected, they’re not only more likely to join a trial— they’re more likely to stay engaged throughout it. ## **Getting Representation Right From the Start** When sponsors and CROs involve communities of color early and *really* listen to what they have to say, they can reduce recruitment risk in pharma. They’re able to achieve stronger participant engagement, more reliable data, and better outcomes for everyone.  At Acclinate, it’s never about checking a box or simply mitigating trial delays through inclusion. We collaborate with sponsors, CROs, and communities to build genuine relationships. We get representation right from the start. That’s the best way to minimize recruitment risk. [Schedule a 1:1 meeting with our team](https://www.acclinate.com/request-a-demo) to learn more. ## Recent Posts [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [ Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) June 25, 2026 3 Min Read Drug development economics are changing. Sponsors are increasingly relying on a single pivotal trial to support approval. Though the goal of this appr... Read More [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [ Clinical Trial Generalizability: What Regulators Will Scrutinize Next ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) June 25, 2026 3 Min Read For years, generalizability was framed as a methodological concern. Reviewers debated whether results could reasonably extend beyond a trial’s enrolle... Read More [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [ Site Engagement Index (SEI): Measuring What Actually Builds Trust ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) June 25, 2026 3 Min Read Clinical research lacks anything but metrics. Enrollment targets, site activation timelines, and digital engagement rates are tracked closely across s... Read More [![](https://blog.acclinate.com/hubfs/Imported_Blog_Media/6567a9f90c0cf111067913e2_Merck%20Pop%20Up2.png) ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) [ Acclinate to support Merck's oncology clinical trials ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) June 24, 2026 1 Min Read Acclinate, an expert in health equity through inclusive research, is collaborating with Merck, known as MSD outside the United States and Canada, to h... Read More [![Why Trial Diversity Is Now a Risk Management Strategy](https://blog.acclinate.com/hubfs/Why-Trial-Diversity-Is-Now-a-Risk-Management-Strategy.jpg) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [ The New Control Lever: Why Trial Diversity Is Now a Risk Management Strategy ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) March 2, 2026 3 Min Read For years, conversations around trial diversity were framed as ethical or reputational concerns. That framing no longer reflects regulatory reality. Read More [![Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity](https://blog.acclinate.com/hubfs/AdobeStock_470269560.webp) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [ Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) February 16, 2026 3 Min Read Clinical research equity efforts originate with good intentions. But they often hit a roadblock in practice: communities are asked to participate in h... Read More [![How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust](https://blog.acclinate.com/hubfs/AdobeStock_1631551849.webp) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [ How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) February 9, 2026 3 Min Read Reaching underrepresented communities in healthcare research has never been simple. Participation decisions are shaped by lived experience, historical... Read More [![Data-Driven Inclusion](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Acclinate-Data-Driven-Inclusion.jpg) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [ Data-Driven Inclusion: Predictive Analytics for Trial Enrollment ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) February 2, 2026 2 Min Read Subpar enrollment remains one of the most common causes of trial delays. But sponsors often miss a key factor: underrepresentation. Lack of diversity ... Read More [![Exploring Diversity in Clinical Research With Acclinate](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Exploring-Diversity-in-Clinical-Research-With-Acclinate.jpg) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [ Exploring Diversity in Clinical Research With Acclinate ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) January 26, 2026 3 Min Read Diversity in clinical research remains a widely discussed goal, yet progress has been uneven. Trials still grapple with subpar representation, limited... Read More [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) June 25, 2026 Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World Read More ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) June 25, 2026 Clinical Trial Generalizability: What Regulators Will Scrutinize Next Read More ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) June 25, 2026 Site Engagement Index (SEI): Measuring What Actually Builds Trust Read More ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) ![Woman wearing Acclinate Shirt](https://blog.acclinate.com/hs-fs/hubfs/layer1_image.webp?width=1600&height=1068&name=layer1_image.webp) ![Medical Research Software e-DICT](https://blog.acclinate.com/hs-fs/hubfs/layer2_image.webp?width=885&height=885&name=layer2_image.webp) ![layer2.2_image](https://blog.acclinate.com/hs-fs/hubfs/layer2.2_image.webp?width=1505&height=1197&name=layer2.2_image.webp) ![layer3_image](https://blog.acclinate.com/hs-fs/hubfs/layer3_image.webp?width=1600&height=1067&name=layer3_image.webp) ## Ready to Measure Your True Impact? Partner with Acclinate to turn mission into measurable, data-driven action. [ Get Started ](https://www.acclinate.com/contact-us) [![Acclinate Logo Reversed](https://blog.acclinate.com/hs-fs/hubfs/footer_logo.png?width=1600&height=398&name=footer_logo.png "Acclinate Logo Reversed")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [e-DICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [CROs](https://www.acclinate.com/solutions/for-cros) - [Community Partners](https://www.acclinate.com/solutions/community-partners) - Resources - [Resources Hub](https://www.acclinate.com/resources) - [Glossary](https://www.acclinate.com/glossary) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [News](https://news.acclinate.com/) - [Blog](https://blog.acclinate.com/) - [FAQs](https://www.acclinate.com/faq) - Company - [About us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [Contact Us](https://www.acclinate.com/contact-us) - Follow Us - [** Linkedin](https://www.linkedin.com/company/acclinateinc/) - [Privacy Policy](https://www.acclinate.com/privacy) - [Terms of Service](https://www.acclinate.com/terms-of-use-acclinate) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Acclinate", "url" : "https://blog.acclinate.com/author/acclinate" }, "dateModified" : "2026-06-18T19:48:40.801Z", "datePublished" : "2025-08-20T13:30:00.000Z", "headline" : "Reduce Recruitment Risk in Pharma Through Representation | Acclinate", "image" : [ "https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Reduce-Recruitment-Risk-in-Pharma-Through-Representation.jpg" ], "mainEntityOfPage" : { "@id" : "https://blog.acclinate.com/reduce-recruitment-risk-in-pharma-through-representation", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.acclinate.com/hubfs/Acclinate-logo.png" }, "name" : "Acclinate" } } ```